Evidence map›Paper›PMID 19263190›Full record

Trial reportInternational journal of hematology2009

Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.

Hisashi Sakamaki, Ken-Ichi Ishizawa, Masafumi Taniwaki, Shin Fujisawa, Yasuo Morishima, Kensei Tobinai, Masaya Okada, Kiyoshi Ando, Noriko Usui, Shuichi Miyawaki and 13 more

Abstract readClinical Trial, Phase IClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in International journal of hematology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 31 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 20 institutions in 1 country.

Hisashi SakamakiDepartment of Hematology, Metropolitan Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan. sakamaki@cick.jp.
Ken-Ichi IshizawaTohoku University, Sendai, Japan.
Masafumi TaniwakiKyoto Prefectural University of Medicine, Kyoto, Japan.
Shin FujisawaYokohama City University Medical Center, Yokohama, Japan.
Yasuo MorishimaAichi Cancer Center, Nagoya, Japan.
Kensei TobinaiNational Cancer Center, Tokyo, Japan.
Masaya OkadaHyogo Medical University, Nishinomiya, Japan.
Kiyoshi AndoTokai University, Isehara, Japan.
Noriko UsuiJikei University School of Medicine, Tokyo, Japan.
Shuichi MiyawakiSaiseikai Maebashi Hospital, Maebashi, Japan.
Atae UtsunomiyaJiaikai Imamura Hospital Branch Hospital, Kagoshima, Japan.
Nobuhiko UoshimaMatsushita Memorial Hospital, Moriguchi, Japan.
Tadashi NagaiJichi Medical School, Shimotsuke, Japan.
Tomoki NaoeNagoya University, Nagoya, Japan.
Toshiko MotojiTokyo Women's Medical University, Tokyo, Japan.
Itsuro JinnaiSaitama Medical University, Iruma, Japan.
Mitsune TanimotoOkayama University, Okayama, Japan.
Yasushi MiyazakiNagasaki University, Nagasaki, Japan.
Kazunori OhnishiHamamatsu University School of Medicine, Hamamatsu, Japan.
Shinsuke IidaNagoya City University, Nagoya, Japan.
Shinichiro OkamotoKeio University, Tokyo, Japan.
Taku SeriuBristol-Myers K.K., Tokyo, Japan.
Ryuzo OhnoAichi Shukutoku University, Nagoya, Japan.
Aichi Cancer Center · JPAichi Shukutoku University · JPBristol-Myers Squibb (Japan) · JPGunma Saiseikai Maebashi Hospital · JPHamamatsu University · JPHyogo University · JPImamura Hospital · JPJichi Medical University · JPJikei University School of Medicine · JPKeio University · JPKyoto Prefectural University of Medicine · JPMatsushita Memorial Hospital · JPNagasaki University · JPNagoya City University · JPNagoya University · JPOkayama University · JPSaitama Medical University · JPTohoku University · JPTokai University · JPTokyo Metropolitan Komagome Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A phase 1/2 study was conducted to assess the safety and efficacy of dasatinib in Japanese patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+) ALL) resistant or intolerant to imatinib. In phase 1, 18 patients with chronic phase (CP) CML were treated with dasatinib 50, 70, or 90 mg twice daily to evaluate safety. Dasatinib <or= 90 mg twice daily was well tolerated. In phase 2, dasatinib 70 mg was given twice daily to CP-CML patients for 24 weeks and to CML patients in accelerated phase (AP)/blast crisis (BC) or Ph(+) ALL for 12 weeks. In the CP-CML group (n = 30) complete hematologic response was 90% and major cytogenetic response (MCyR) 53%. In the AP/BC-CML group (n = 11) major hematologic response (MaHR) was 64% and MCyR 27%, whereas in the Ph(+) ALL group (n = 13) MaHR was 38% and MCyR 54%. Dasatinib was well tolerated and most of the nonhematologic toxicities were mild or moderate. Dasatinib therapy resulted in high rates of hematologic and cytogenetic response, suggesting that dasatinib is promising as a new treatment for Japanese CML and Ph(+) ALL patients resistant or intolerant to imatinib.

Indexed as

AdultAgedAntineoplastic AgentsAsian PeopleDasatinibFusion Proteins, bcr-ablHumansLeukemia, Myeloid, Chronic-PhaseMiddle AgedMutationPrecursor Cell Lymphoblastic Leukemia-LymphomaPyrimidinesThiazolesAntineoplastic AgentsDasatinibFusion Proteins, bcr-ablPyrimidinesThiazoles

Identifiers

PMID19263190
OpenAlexW1965749310

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.